M&A / Deals Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide Pharmaceutical Business ReviewThe agreement covers Hanmi's candidate that uses its LAPSCOVERY long-acting platform technology.Metabolic & GLP-1Read full story pharminent June 1, 2026 (Last updated: June 1, 2026) Pharmaceutical Business Review The agreement covers Hanmi’s candidate that uses its LAPSCOVERY long-acting platform technology. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapyNext: ASCO: Summit reached with China lung data but new climb begins to prove global benefit Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
